Integrum (INTEG) investor relations material

Executive summary

• Achieved record number of S1 surgeries in Q4, reflecting operational improvements and increased patient inflow.

• Organisational changes focused on commercial efficiency and cost control were implemented, especially in the US and Ukraine.

• Launched a digital patient portal in the US post-period to enhance patient flow and awareness.

Financial highlights

• Q4 net sales were SEK 25.1 million, down 7.7% year-over-year, mainly due to currency effects.

• Q4 operating loss was SEK -20.1 million, impacted by SEK 15 million in non-recurring items; adjusted operating loss was SEK -5 million.

• Full-year net sales were SEK 91.4 million, up 0.3% year-over-year; operating loss widened to SEK -53.2 million.

• Gross margin for the year was 64% (down from 76%), affected by currency, tariffs, and a one-off reclassification of surgical instruments.

• Cash flow for the year was SEK -20.5 million, with cash and cash equivalents at SEK 19.1 million at year-end.

Outlook and guidance

• Management expects improved results and a stable foundation due to cost reductions, organisational adjustments, and completed financing.

• Focus remains on long-term growth, profitability, and expanding solutions for amputees globally.